DGAP-News: Evonik Industries AG
/ Key word(s): 9 Month figures
Key Financial Data: Third quarter 2019 - 2019: Adjusted EBITDA to remain at least stable - Free cash flow outlook for full year confirmed and specified: around EUR700 million - Q3: Sales and operating earnings below year-ago period - Stricter cost discipline supports earnings Essen, Germany. Evonik is sticking to its full-year earnings outlook despite an ongoing weakness in the global economy. The company expects adjusted EBITDA to remain at least stable compared with last year. Sales are now expected to be slightly lower than the previous year because of lower demand. Evonik had expected sales to remain stable. In 2018 Evonik generated - excluding the divested Methacrylates business - sales of "We prepared ourselves at an early stage with stricter cost discipline and additional contingency measures for a cooling global economy," said Christian Kullmann, chairman of Evonik's executive board. "We are being very proactive to ensure we meet our full-year outlook." The 2018 initiated efficiency program to reduce administrative and selling expenses by EUR200 million annually has been accelerated. By end of this year, Evonik will achieve EUR120 million of savings, EUR20 million more than originally planned. A further EUR20 million will be saved with additional contingency measures such as delaying new hires and more restrictive expenditure on external services. Evonik is specifying its full-year outlook for free cash flow and is now expecting a level of around EUR700 million, a significantly higher free cash flow compared with last year. This is mainly due to lower capex spending, less build-up of net working capital and the partial reimbursement of pension payments from the Contractual Trust Arrangement (CTA). The more precise outlook does not include taxes incurred from the carve out of the divested Methacrylates business. The global economic slowdown continued to impact Evonik's performance in the third quarter. In the months July to September sales fell 3 percent to EUR3.23 billion due to lower volumes and selling prices. Adjusted EBITDA fell 6 percent year-on-year to EUR543 million. Segment Performance Nutrition & Care: Sales declined 2 percent to EUR1.14 billion in the third quarter. Demand for essential amino acids for animal nutrition remained high while selling prices declined further. In the Health Care business sales increased, especially due to good demand for pharma and food ingredients. Sales increased significantly for polyurethane-foam additives, mostly on high demand for durable consumer goods and insulation. Adjusted EBITDA at the segment dropped 11 percent to EUR188 million.
Disclaimer Contact: Tim Lange Head of Investor Relations Phone +49 201 177-3150 tim.lange@evonik.com Evonik Industries AG
Supervisory Board
Registered Office is Essen
05.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Evonik Industries AG |
Rellinghauser Straße 1-11 | |
45128 Essen | |
Germany | |
Phone: | +49 (0) 201 177-01 |
Fax: | +49 (0) 201 177-3475 |
E-mail: | investor-relations@evonik.com |
Internet: | www.evonik.com |
ISIN: | DE000EVNK013 |
WKN: | EVNK01 |
Indices: | MDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange |
EQS News ID: | 903797 |
End of News | DGAP News Service |
903797 05.11.2019